BRAF inhibitors, such as Dabrafenib and PLX8394, have shown promise in GBM carrying mutations in the oncogene Ser/Threo-protein kinase B-Raf (proto-oncogene B-Raf) especially in cases that failed standard therapy (TMZ, carboplatin). The gene discussed is BRAF; the disease is glioblastoma.